Location:Home > Faculty > Faculty and Staff
Faculty and Staff
Faculty and Staff
Zhou Bing

Principal Investigator
Academic title:
Personal Website:
Postal Code:
Mailing Address:
Room 3508, 555 Zu Chong Zhi Road, Pudong, Shanghai, P.R.China

Prof. Zhou currently is a Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Prof. Zhou received his BSc from Tongji University in 2004, and his MSc from Tongji University in 2007. After he obtained his PhD at Shanghai Institute of Materia Medica (SIMM) in 2011, he joined the laboratory of Prof. Arun K. Ghosh at Purdue University as a postdoctoral fellow. In 2013, he moved to Prof. Shaomeng Wang’s group at the University of Michigan as a postdoctoral fellow. Since March 2016, Prof. Zhou has worked at SIMM as a Principal investigator. Prof. Zhou’s primary interest is the development of novel small-molecule therapeutics for the treatment of cancer focusing on targeting novel epigenetic enzymes and important protein-protein interactions. Prof. Zhou has published more than 50 peer-reviewed papers with more than 1000 citations and is also an inventor of 15 patents. Several patents have been licensed out by Medivation and Medsyn Biopharma.

2008.9- 2011.6 Ph.D., Shanghai Institute of Meteria Medica, Chinese Academy of Sciences
2004.9- 2007.3 M.S., Tongji University
2000.9- 2004.6 B.S., Tongji University

2016.3–Present, Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2013.4-2016.3, Postdoctoral Research Fellow, Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
2011.6-2013.3, Postdoctoral Research Fellow, Department of Chemistry, Purdue University, West Lafayette, Indiana, USA
2007.4-2008.8, Assistant researcher, Hutchison MediPharma Limited

Research Directions

Dr. Zhou’s primary interest is the development of novel small-molecule therapeutics for the treatment of cancer focusing on targeting novel epigenetic enzymes and important protein-protein interactions, by utilizing drug design, medicinal chemical biology, and medicinal chemistry.
1) Synthesis of chemical probes for epigenetic targets
2) The development of small-molecule inhibitors of protein-protein interactions
3) Modification of natural products for the treatment of cancer
4) The development of transition-metal-catalyzed C-H activation and their application in the medicinal chemistry

Social Titles

Awards & Honors

2017, Shanghai Rising-Star Program


1) Design and synthesis of novel small-molecule BET Bromodomain Inhibitors. This technology was covered by two patents and have been out-licensed to Medivation Inc.
2) Design and synthesis of novel protein degraders. This technology was covered by three patents and have been licensed by Medsyn Biopharma LLC.
3) Design and synthesis of a series of novel triptolide derivatives possessing remarkable anticancer activity.
4)Total Synthesis of 7 natural products including: Triptolide, Tripdiolide, (-)-α-Kainic acid, Goniomitine, (+)-Lithospermic acid, 1-deoxynojirimycin and valienamine.
5) Development of a series of C–H activation reactions to form new C–C, S–C, N–C, O–C, bonds.

Grants & Research Projects



1. Bing Zhou, Jiantao Hu, Fuming Xu, Zhuo Chen, Longchuan Bai, Ester Fernandez-Salas, Mei Lin, Liu Liu, Chao-Yie Yang, Yujun Zhao, Donna McEachern, Sally Przybranowski, Bo Wen, Duxin Sun, and Shaomeng Wang* J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01816
2. Longchuan Bai,# Bing Zhou (co-first author),# Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Hui Jiang, Jiantao Hu, Fuming Xu, Yujun Zhao, Liu Liu, Ester Fernandez-Salas, Jing Xu, Yali Dou, Bo Wen, Duxin Sun, Jennifer Meagher, Jeanne Stuckey, Daniel F. Hayes, Shunqiang Li, Matthew J. Ellis and Shaomeng Wang.* Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017, 77, 2476-2487.
3. Yunxiang Wu, Bing Zhou*. Ruthenium-Catalyzed Direct Hydroxymethylation of Aryl C–H Bonds. ACS Catal., 2017, 7 , 2213.
4. Wei Hou, Yaxi Yang, Yunxiang Wu, Huijin Feng, Yuanchao Li and Bing Zhou,* Rhodium(III)-catalyzed alkylation of primary C(sp3)–H bonds with α-diazocarbonyl compounds. Chem. Commun., 2016, 52, 9672-9675.
5. Yaxi Yang, Xuan Wang, Yuanchao Li, and Bing Zhou* A [4+1] Cyclative Capture Approach to 3H-Indole-N-oxides at RoomTemperature by Rhodium(III)-Catalyzed C-H Activation. Angew. Chem. Int. Ed. 2015, 54, 15400-15404.
6. Bing Zhou,* Zhaoqiang Chen, Yaxi Yang,* Wen Ai, Huanyu Tang, Yunxiang Wu, Weiliang Zhu,* Yuanchao Li. Rhodium-Catalyzed Redox-Neutral C-H Functionalization of Arylamine N-Oxides with Diazo Compounds: Primary C(sp3)-H/C(sp2)-H Activation and Oxygen Atom Transfer. Angew. Chem. Int. Ed. 2015, 54, 12121-12126.
7. Wen Ai, Yunxiang Wu, Huanyu Tang, Xueyan Yang, Yaxi Yang,* Yuanchao Li and Bing Zhou.* Rh(III)- or Ir(III)-catalyzed ynone synthesis from aldehydes via chelation-assisted C–H bond activation. Chem. Commun., 2015, 51, 7871-7874.
8. Wen Ai, Xueyan Yang, Yunxiang Wu, Xuan Wang, Yuanchao Li, Yaxi Yang,* and Bing Zhou.* Rh(III)- and Ir(III)-Catalyzed C7-Alkylation of Indolines with Diazo Compounds. Chem. Eur. J. 2014, 20, 17653.
9. Yunxiang Wu , Yaxi Yang , Bing Zhou,* and Yuanchao Li.* Iridium(III)-Catalyzed C-7 Selective C–H Alkynylation of Indolines at Room Temperature. J. Org. Chem., 2015, 80, 1946–1951.
10. Xuan Wang , Huanyu Tang , Huijin Feng , Yuanchao Li *, Yaxi Yang *, and Bing Zhou.* Access to Six- and Seven-Membered 1,7-Fused Indolines via Rh(III)-Catalyzed Redox-Neutral C7-Selective C–H Functionalization of Indolines with Alkynes and Alkenes. J. Org. Chem., 2015, 80, 6238–6249.
11. Bing Zhou,* Yaxi Yang, Huanyu Tang, Juanjuan Du, Huijin Feng, and Yuanchao Li, Rh(III)-Catalyzed Intramolecular Redox-Neutral or Oxidative Cyclization of Alkynes: Short, Efficient Synthesis of 3,4-Fused Indole Skeletons. Org. Lett., 2014, 16, 3900–3903 (highlighted in SYNFACTS, 2014, 1021).
12. Bing Zhou*, Juanjuan Du, Yaxi Yang andYuanchao Li*. Rhodium(III)-Catalyzed Intramolecular Redox-Neutral Annulation of Tethered Alkynes: Formal Total Synthesis of (±)-Goniomitine. Chem. Eur. J. 2014, 20, 12768. (Highlighted by Organic Chemistry Portal, 2015, June 22).
13. Bing Zhou*, Juanjuan Du, Yaxi Yang*, Huijin Feng, and Yuanchao Li. Rh(III)-Catalyzed C–H Amidation with N-Hydroxycarbamates: A New Entry to N-Carbamate-Protected Arylamines. Org. Lett., 2014, 16, 592–595.
14. Bing Zhou*, Wei Hou, Yaxi Yang, Huijin Feng, and Yuanchao Li.* Copper(I)-Catalyzed Aryl or Vinyl Addition to Electron-Deficient Alkenes Cascaded by Cationic Cyclization. Org. Lett., 2014, 16, 1322–1325.
15. Yaxi Yang, Wei Hou, Lihuai Qin, Juanjuan Du, Huijin Feng, Bing Zhou* and Yuanchao Li.* Rhodium-Catalyzed Directed Sulfenylation of Arene C-H Bonds. Chem. Eur. J. 2014, 20, 416-420.
16. Juanjuan Du, Yaxi Yang, Huijin Feng, Yuanchao Li* and Bing Zhou.* Rhodium-Catalyzed Direct Amination of Arenes with Nitrosobenzenes: A New Route to Diarylamines. Chem. Eur. J. 2014, 20, 5727-5731.

1. Shaomeng Wang, Bing Zhou, Yang Hu, Chao-Yie Yang. Fused 1,4-Oxazepines and Related Analogs as BET Bromodomain Inhibitors. United State, 62/295,271.
2. Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang, BET PROTEIN DEGRADERS. United State, 62/321,499.
3. Shaomeng Wang; Yujun Zhao; Bing Zhou; Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, and Ting Zhao, 9H-Pyrimido[4,5-B]indoles and Related Analogs as BET Bromodomain Inhibitors, PCT, US2015/017908.
4. Shaomeng Wang; Xu Ran; Yujun Zhao; Chao-Yie Yang; Liu Liu; Longchuan Bai; Donna McEachern; Jeanne Stuckey; Jennifer Lynn Meagher; Duxin Sun; Xiaoqin Li; Bing Zhou; Hacer Karatas; Ruijuan Luo; Arul Chinnaiyan; Irfan A. Asangani; BET Bromodomain Inhibitors and therapeutic Methods Using the same, PCT, US2014/022953.
5. Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, MDM2 PROTEIN DEGRADERS. United State, 62/409,571.
6. Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Monofunctional Intermediates For Ligand-Dependent Target Protein Degradation. United State, 62/409,592.